166 related articles for article (PubMed ID: 31900912)
1. Canonical and Noncanonical Androgen Metabolism and Activity.
Storbeck KH; Mostaghel EA
Adv Exp Med Biol; 2019; 1210():239-277. PubMed ID: 31900912
[TBL] [Abstract][Full Text] [Related]
2. Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.
Mostaghel EA
Int J Biol Sci; 2014; 10(6):602-13. PubMed ID: 24948873
[TBL] [Abstract][Full Text] [Related]
3. Androgens in prostate cancer: A tale that never ends.
Hou Z; Huang S; Li Z
Cancer Lett; 2021 Sep; 516():1-12. PubMed ID: 34052327
[TBL] [Abstract][Full Text] [Related]
4. Steroidogenesis in castration-resistant prostate cancer.
Shiota M; Endo S; Blas L; Fujimoto N; Eto M
Urol Oncol; 2023 May; 41(5):240-251. PubMed ID: 36376200
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
6. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC
du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC
J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701
[TBL] [Abstract][Full Text] [Related]
7. The role of adrenal derived androgens in castration resistant prostate cancer.
Barnard M; Mostaghel EA; Auchus RJ; Storbeck KH
J Steroid Biochem Mol Biol; 2020 Mar; 197():105506. PubMed ID: 31672619
[TBL] [Abstract][Full Text] [Related]
8. Steroid hormone synthetic pathways in prostate cancer.
Mostaghel EA
Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
[TBL] [Abstract][Full Text] [Related]
10. 11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored.
Pretorius E; Africander DJ; Vlok M; Perkins MS; Quanson J; Storbeck KH
PLoS One; 2016; 11(7):e0159867. PubMed ID: 27442248
[TBL] [Abstract][Full Text] [Related]
11. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.
Mostaghel EA; Nelson PS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):243-58. PubMed ID: 18471783
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard A; Evans CP; Gao AC
Mol Cancer Ther; 2017 Jan; 16(1):35-44. PubMed ID: 27794047
[TBL] [Abstract][Full Text] [Related]
13. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
Pham S; Deb S; Ming DS; Adomat H; Hosseini-Beheshti E; Zoubeidi A; Gleave M; Guns ES
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
[TBL] [Abstract][Full Text] [Related]
14. Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.
Zhang A; Zhang J; Plymate S; Mostaghel EA
Horm Cancer; 2016 Apr; 7(2):104-13. PubMed ID: 26797685
[TBL] [Abstract][Full Text] [Related]
15. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
16. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?
Storbeck KH; Bloem LM; Africander D; Schloms L; Swart P; Swart AC
Mol Cell Endocrinol; 2013 Sep; 377(1-2):135-46. PubMed ID: 23856005
[TBL] [Abstract][Full Text] [Related]
17. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
18. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
19. [Molecular genetic mechanisms of drug resistance in prostate cancer].
Krasnov GS; Dmitriev AA; Sadritdinova AF; Volchenko NN; Slavnova EN; Danilova TV; Snezhkina AV; Melnikova NV; Fedorova MS; Lakunina VA; Belova AA; Nyushko KM; Alekseev BY; Kaprin AD; Kudryavtseva AV
Mol Biol (Mosk); 2015; 49(5):716-27. PubMed ID: 26510590
[TBL] [Abstract][Full Text] [Related]
20. Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment.
Fiandalo MV; Wilton J; Mohler JL
Int J Biol Sci; 2014; 10(6):596-601. PubMed ID: 24948872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
